个性化参与式医学：分享知识与不确定性。
Personalized participatory medicine: sharing knowledge and uncertainty.
机构信息
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
出版信息
Genome Med. 2011 Oct 27;3(10):69. doi: 10.1186/gm285.
Abstract
Informing patients about risks and benefits of alternative treatment options and choosing between them is becoming a bigger challenge as knowledge about the relationship between the individual's genetic profile and the efficacy and safety of available medications accumulates. Putting personalized medicine into practice requires new modes of information sharing and decision making by patient and physician. This is illustrated by a case study on treatment choices of breast cancer patients following genotyping for CYP2D6, recently published in Genome Medicine.See research article: http://genomemedicine.com/content/3/10/64.
摘要
随着关于个体基因谱与现有药物疗效和安全性之间关系的知识不断积累，向患者告知替代治疗方案的风险和益处并在其中进行选择正变得越来越具有挑战性。将个性化医学付诸实践需要患者和医生采用新的信息共享和决策模式。最近在《基因组医学》杂志上发表的一篇关于 CYP2D6 基因分型后乳腺癌患者治疗选择的病例研究说明了这一点。参见研究文章：http://genomemedicine.com/content/3/10/64。
相似文献
1
Personalized participatory medicine: sharing knowledge and uncertainty.个性化参与式医学：分享知识与不确定性。
Genome Med. 2011 Oct 27;3(10):69. doi: 10.1186/gm285.
3
Understanding behavioral intent to participate in shared decision-making in medically uncertain situations.理解在医学情况不确定时参与共同决策的行为意图。
Methods Inf Med. 2012;51(4):301-8. doi: 10.3414/ME11-01-0077. Epub 2012 Jul 20.
4
Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.他莫昔芬对激素受体阳性乳腺癌女性的益处及CYP2D6检测
Clin J Oncol Nurs. 2013 Apr;17(2):174-9. doi: 10.1188/13.CJON.174-179.
5
Next-generation personalized drug discovery: the tripeptide GHK hits center stage in chronic obstructive pulmonary disease.下一代个性化药物发现：三肽 GHK 在慢性阻塞性肺疾病中崭露头角。
Genome Med. 2012 Sep 21;4(9):70. doi: 10.1186/gm371. eCollection 2012.
6
Decision aids for people facing health treatment or screening decisions.为面临健康治疗或筛查决策的人群提供的决策辅助工具。
Cochrane Database Syst Rev. 2014 Jan 28(1):CD001431. doi: 10.1002/14651858.CD001431.pub4.
7
CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.CYP2D6 基因分型与他莫昔芬：个体化医学探索中尚未完成的篇章。
Semin Oncol. 2011 Apr;38(2):263-73. doi: 10.1053/j.seminoncol.2011.01.002.
8
Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis.参与式医学和患者赋权在多发性硬化症中的个性化医疗。
Expert Rev Neurother. 2012 Mar;12(3):343-52. doi: 10.1586/ern.11.161.
9
Characteristics of physicians with participatory decision-making styles.具有参与式决策风格的医生的特征。
Ann Intern Med. 1996 Mar 1;124(5):497-504. doi: 10.7326/0003-4819-124-5-199603010-00007.
10
Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study.基于网络的溃疡性结肠炎患者决策辅助工具的开发与可行性：定性试点研究。
J Med Internet Res. 2021 Feb 25;23(2):e15946. doi: 10.2196/15946.
引用本文的文献
1
Informed decision-making among students analyzing their personal genomes on a whole genome sequencing course: a longitudinal cohort study.在全基因组测序课程中分析个人基因组的学生中进行知情决策：一项纵向队列研究。
Genome Med. 2013 Dec 30;5(12):113. doi: 10.1186/gm518. eCollection 2013.
2
From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi's clinical story.从P0到P6医学：一种高度参与性、叙事性、互动性和“增强型”医学模式——关于萨尔瓦托雷·亚科内西临床故事的几点思考
Patient Prefer Adherence. 2013 Apr 24;7:353-9. doi: 10.2147/PPA.S38578. Print 2013.
3
Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.向早期乳腺癌患者传递基因组复发风险估计：肿瘤学家的观点。
Psychooncology. 2013 Sep;22(9):2110-6. doi: 10.1002/pon.3264. Epub 2013 Feb 28.
本文引用的文献
1
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.药物遗传学检测会影响考虑他莫昔芬治疗的女性对治疗方案的选择。
Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280.
2
Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.根据 CYP2D6 基因型和依西美坦水平增加乳腺癌患者的他莫昔芬剂量：对活性代谢物异构体和抗雌激素活性评分的影响。
Clin Pharmacol Ther. 2011 Oct;90(4):605-11. doi: 10.1038/clpt.2011.153. Epub 2011 Sep 7.
3
Genomics and drug response.基因组学与药物反应。
N Engl J Med. 2011 Mar 24;364(12):1144-53. doi: 10.1056/NEJMra1010600.
4
Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.依西美坦，乳腺癌治疗的新基石：在健康人体受试者中证明安全性、耐受性和全身生物利用度。
Clin Pharmacol Ther. 2010 Dec;88(6):814-7. doi: 10.1038/clpt.2010.196. Epub 2010 Oct 27.
5
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.强效 CYP2D6 抑制剂不会增加接受辅助他莫昔芬治疗的早期乳腺癌患者的复发率。
Breast Cancer Res Treat. 2011 Jan;125(2):505-10. doi: 10.1007/s10549-010-1008-7. Epub 2010 Jul 1.
6
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.细胞色素 P450 2D6 与辅助他莫昔芬治疗结局：荟萃分析结果。
Breast Cancer Res Treat. 2010 Aug;122(3):609-17. doi: 10.1007/s10549-010-0902-3. Epub 2010 May 8.
7
Clinical assessment incorporating a personal genome.纳入个人基因组的临床评估。
Lancet. 2010 May 1;375(9725):1525-35. doi: 10.1016/S0140-6736(10)60452-7.
8
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.CYP2D6基因多态性与接受他莫昔芬治疗的早期乳腺癌女性患者预后之间的关联。
JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.
9
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.细胞色素P450 2D6代谢对接受他莫昔芬辅助治疗的女性的影响。
Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18.
10
Pharmacogenetics in the laboratory and the clinic.实验室及临床中的药物遗传学
N Engl J Med. 2003 Feb 6;348(6):553-6. doi: 10.1056/NEJMe020173.
Zotero 插件